Arcadia Biosciences Welcomes Dr. Randy Shultz as Head of Research and Development
-- Experienced R&D strategist brings deep expertise in advanced breeding and gene editing technologies--
Shultz has nearly 20 years of experience in plant science and agricultural biotechnology. The former global crop lead at Inari Agriculture, he also served there as the director of R&D and senior director of R&D strategy. Shultz was the first key scientific hire at Inari, and played an instrumental role in building a scalable R&D platform and developing a foundational intellectual property estate. Before Inari, Shultz spent several years leading various scientific production teams at Monsanto (now Bayer Crop Science), including their Genome Editing Platform team.
“Throughout his career, Randy has established a reputation as a keen R&D strategist, driving products through the pipeline from invention through commercial planning,” said Raj Ketkar, Arcadia’s president and CEO. “With his deep expertise in gene editing and new plant breeding technologies, he will be exploring new partnerships and licensing opportunities to expand our platform of tools to improve crops. We are thrilled to have a science leader of Randy’s caliber as we build our capabilities in cannabis and advance future innovations in our GoodWheat portfolio of novel wheat attributes.”
“Arcadia is an innovative company with a strong technology foundation and rich pipeline of novel products,” said Shultz. “I look forward to working with Arcadia’s team of world-class scientists as we build the next generation of products, bringing value to growers and downstream partners.”
Shultz received his Ph.D. in functional genomics from
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are subject to risks and uncertainties that
could cause actual results to differ materially, and reported results
should not be considered as an indication of future performance. These
risks and uncertainties include, but are not limited to: the company’s
expectations of Randy Shultz’s potential contributions as an executive
on the leadership team; and the other risks set forth in the company’s
filings with the